BioCryst   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Durham NC United States (1986)

Organization Overview

First Clinical Trial
1999
NCT00002237
First Marketed Drug
2014
peramivir (rapivab)
First NDA Approval
2014
peramivir (rapivab)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BIOCRYST | BioCryst Pharmaceuticals | BIOCRYST PHARMACEUTICALS INC

Indications

Approved Indications


 

Influenza, Human

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angioedema (Phase 3)

Angioedemas, Hereditary (Phase 3)

Arthritis (Phase 2)

Communicable Diseases (Phase 1)

Fatigue (Phase 3)

Fever (Phase 1)

Filoviridae Infections (Phase 1)

Gout (Phase 2)

Headache (Phase 3)

Hemoglobinuria (Phase 2)

Hemoglobinuria, Paroxysmal (Phase 2)

Hemorrhagic Fever, Ebola (Phase 1)

HIV Infections (Phase 1)

Hyperuricemia (Phase 2)

Infections (Phase 1)

Influenza, Human (Phase 3)

Joint Diseases (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, T-Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Marburg Virus Disease (Phase 1)

Myalgia (Phase 3)

Pharyngitis (Phase 3)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Renal Insufficiency (Phase 2)

Virus Diseases (Phase 1)

Yellow Fever (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 57
  • # of Trial APIs: 25